Ming Li, Ph.D.
Associate Professor of Pharmacology
Tulane Cancer Center Contributing Member
Address: 1430 Tulane Ave., SL-83, New Orleans, LA 70112
Dr. Li received his Ph.D. from the University of Iowa in 1989 and conducted post-doctoral research at the University of Washington from 1990 to 1993. The main interest of research in Dr. Ming's laboratory is to study the role of Ca2+ channels in the development of human diseases, especially in breast cancer. Ca2+ channels have long been known to be involved in the regulation of a variety of biological functions ranging from the control of cell excitability to the regulation of cell exocytosis and proliferation. We have reported the expression of T-type Ca2+ channels in breast cancer tumor cells and mitogenic cell lines. We have also found that the rate of proliferation of these cell lines could be reduced by our newly developed selective T-type Ca2+ channel antagonists. We are characterizing the pharmacokinetics and pharmacodynamics of these compounds as well as their anti-tumor effect in animal experiments. The goal of this project is to search for a new drug in the implement of the treatment of human breast cancer.
Wang L, Hu F, Bhattacharjee A, Zuo Z, Honkanen RE, Berggren P-O, Li M: A low-voltage-activated Ca2+ current mediates cytokine-induced pancreatic b-cell death. Endocrinology. 140:1200-1204 (1999)
Huang L, Keyser BM, Tagmose TM, Hansen JB, Taylor JT, Zhuang H, Zhang M, Ragsdale DS, Li M. NNC 55-0396: A new selective inhibitor of T-type calcium channels. J Pharm Exp Therap DOI:10.1124/jpet.103.060814 (2004)